SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of February 18, 2026, SYRE stock price climbed to $36.60 with 673,030 million shares trading.

SYRE has a beta of 1.94, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.27 to the broad based SPY ETF.

SYRE has a market cap of $2.84 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, IWM, XBI, VXF, IBB.

SYRE has outperformed the market in the last year with a price return of +59.7% while the SPY ETF gained +13.8%. SYRE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +50.2% and +9.9%, respectively, while the SPY returned +3.4% and -0.5%, respectively.

SYRE support price is $34.71 and resistance is $37.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.